诺华：创新性降胆固醇药物乐可为 在华获批

Core Viewpoint - Novartis announced the approval of its innovative cholesterol-lowering drug, Leqvio (inclisiran sodium injection), by the National Medical Products Administration of China for use as an adjunct to diet in adults with primary hypercholesterolemia (non-familial) or mixed dyslipidemia to lower low-density lipoprotein cholesterol (LDL-C) [1] Group 1 - Novartis received approval for Leqvio from the Chinese regulatory authority [1] - The drug is indicated for adults with specific cholesterol-related conditions [1] - Leqvio is intended to be used alongside dietary measures [1]